MOMTAZEE JAMES C — SEC Form 4 filings
SEC reporting owner CIK 1209181. 19 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2024-01-23 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | Director | 16 | — | — | 27 |
| BridgeBio Pharma, Inc. (BBIO) | Director | 3 | — | — | 5 |
Form 4 filings — MOMTAZEE JAMES C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-14 | 4 | Roivant Sciences Ltd. (ROIV) | Tax withholding (F): 2,905 @ $40.94 | EDGAR |
| 2026-07-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 405 @ $0 | EDGAR |
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 469 @ $0 · Tax withholding (F): 94 @ $29.83 | EDGAR |
| 2026-01-22 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 609 @ $0 · Tax withholding (F): 122 @ $22.98 | EDGAR |
| 2025-10-22 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 789 @ $0 · Tax withholding (F): 158 @ $17.74 | EDGAR |
| 2025-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 14,524 @ $0 · Other (J): 3,282 @ $13.77 · Grant/award (A): 33,726 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,201 @ $0 · Tax withholding (F): 241 @ $11.65 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,379 @ $0 · Tax withholding (F): 276 @ $10.15 | EDGAR |
| 2025-01-27 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,248 @ $0 · Tax withholding (F): 306 @ $11.21 | EDGAR |
| 2024-10-23 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,231 @ $0 | EDGAR |
| 2024-09-16 | 4 | Roivant Sciences Ltd. (ROIV) | Other (J): 3,056 @ $12.12 | EDGAR |
| 2024-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 16,406 @ $0 · Grant/award (A): 27,894 (derivative) @ $0 | EDGAR |
| 2024-07-25 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,555 @ $0 | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
| 2024-04-26 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,490 @ $0 · Tax withholding (F): 293 @ $10.90 | EDGAR |
| 2024-01-23 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,570 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1209181 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →